Literature DB >> 1736798

Surgical excision alone is adequate treatment for primary colorectal cancer.

R Hind1, D R Rew, C D Johnson.   

Abstract

This debate examines the arguments for and against the proposal that surgical excision alone is adequate treatment for primary colorectal cancer. The arguments in favour are that the results from curative surgery are excellent and that despite many trials of adjuvant chemotherapy, radiotherapy and immunotherapy, the proposed benefits remain unproven. Recent improvements in surgical technique, particularly for dissection of rectal tumours, have shown the way towards further improvement using surgery alone, and it is clear from a national survey that technical factors related to individual surgeons play a large part in determining recurrence rates. With optimum primary treatment, surgical excision alone is indeed adequate therapy. The arguments against this motion are that although a considerable number of patients do survive with surgery, the 5-year survival rate is poor when there is extensive local invasion or lymphatic metastases. Surgery starts therapy by reducing the tumour load, but other modalities are required to destroy the cells which might subsequently develop into metastases. Trial results with adjuvant therapy are encouraging, although many contain too few patients. We cannot be content with the results of treatment of Dukes' Stage B and C tumours; more trials are needed to determine the best treatment for these patients.

Entities:  

Mesh:

Year:  1992        PMID: 1736798      PMCID: PMC2497502     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  26 in total

1.  Clinical management of advanced gastrointestinal cancer.

Authors:  C G Moertel
Journal:  Cancer       Date:  1975-08       Impact factor: 6.860

2.  Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).

Authors:  A Gérard; M Buyse; B Nordlinger; J Loygue; F Pène; P Kempf; J F Bosset; M Gignoux; J P Arnaud; C Desaive
Journal:  Ann Surg       Date:  1988-11       Impact factor: 12.969

Review 3.  Immunotherapy of human cancers.

Authors:  J R Hobbs
Journal:  BMJ       Date:  1989-11-11

Review 4.  Status of adjuvant therapy for colorectal cancer.

Authors:  R J Mayer; M J O'Connell; J E Tepper; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1989-09-20       Impact factor: 13.506

Review 5.  Adjuvant multimodality treatment of rectal cancer.

Authors:  D J Galloway; A M Cohen; B Shank; M A Friedman
Journal:  Br J Surg       Date:  1989-05       Impact factor: 6.939

6.  Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.

Authors:  F J Panettiere; P J Goodman; J J Costanzi; A B Cruz; V K Vaitkevicius; J D McCracken; R W Brownlee; L Laufman; R L Stephens; J Bonnet
Journal:  J Clin Oncol       Date:  1988-06       Impact factor: 44.544

Review 7.  Adjuvant therapy of colorectal cancer. Why we still don't know.

Authors:  M Buyse; A Zeleniuch-Jacquotte; T C Chalmers
Journal:  JAMA       Date:  1988-06-24       Impact factor: 56.272

Review 8.  Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy.

Authors:  W J Cunliffe; P H Sugarbaker
Journal:  Br J Surg       Date:  1989-10       Impact factor: 6.939

9.  Proliferation characteristics of human colorectal carcinomas measured in vivo.

Authors:  D A Rew; G D Wilson; I Taylor; P C Weaver
Journal:  Br J Surg       Date:  1991-01       Impact factor: 6.939

10.  Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial.

Authors:  J P Arnaud; M Buyse; B Nordlinger; F Martin; J C Pector; P Zeitoun; A Adloff; N Duez
Journal:  Br J Surg       Date:  1989-03       Impact factor: 6.939

View more
  4 in total

1.  Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study.

Authors:  Christopher C L Liao; Anuja Mehta; Nicholas J Ward; Simon Marsh; Tan Arulampalam; John D Norton
Journal:  World J Surg Oncol       Date:  2010-04-26       Impact factor: 2.754

2.  Mass spectrometry protein expression profiles in colorectal cancer tissue associated with clinico-pathological features of disease.

Authors:  Christopher C L Liao; Nicholas Ward; Simon Marsh; Tan Arulampalam; John D Norton
Journal:  BMC Cancer       Date:  2010-08-06       Impact factor: 4.430

3.  Transanal local resection for benign and malignant rectal tumours.

Authors:  E E Piccinini; G Ugolini; G Rosati; A Conti
Journal:  Int J Colorectal Dis       Date:  1995       Impact factor: 2.571

4.  Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.

Authors:  S Ganesh; C F Sier; M M Heerding; J H van Krieken; G Griffioen; K Welvaart; C J van de Velde; J H Verheijen; C B Lamers; H W Verspaget
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.